GlassScriptPhysician profile
Lisa L Kern
NPI 1104989961
$3,408.55
in general payments reported to CMS, 2019-2025
29 companies · $620 in 2025
The $620 reported for 2025 was more than what 77% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $322 · 2022: $859 · 2023: $1,154 · 2024: $455 · 2025: $620.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,228.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,228.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $680.52 | 2021-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $642.29 | 2021-2025 | Farxiga, Brilinta |
| Impulse Dynamics (USA) INC. | $315.29 | 2023-2024 | Optimizer, Optimizer |
| Pfizer INC. | $252.41 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $211.44 | 2022-2023 | Camzyos |
| Bridgebio Pharma, INC. | $152.63 | 2025 | Attruby |
| Abiomed | $114.30 | 2024-2025 | Impella |
| Edwards Lifesciences Corporation | $107.71 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Abbvie INC. | $103.94 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $103.86 | 2022-2023 | Verquvo |
| Novartis Pharmaceuticals Corporation | $101.72 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.65 | 2021-2023 | Jardiance |
| Medtronic, INC. | $67.40 | 2023 | Azure Xt Dr Mri Surescan, Linq II |
| Lexicon Pharmaceuticals, INC. | $55.59 | 2023-2024 | Inpefa |
| Scpharmaceuticals INC. | $54.45 | 2024-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $53.39 | 2023-2024 | Xarelto |
| Novo Nordisk INC | $48.07 | 2021-2025 | Wegovy |
| Baxter Healthcare | $42.04 | 2025 | Perclot |
| Bayer Healthcare Pharmaceuticals INC. | $34.28 | 2023-2024 | |
| Amgen INC. | $31.55 | 2023-2025 | Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $26.55 | 2023 | Aralast |
| Glaxosmithkline, LLC. | $18.14 | 2025 | Nucala |
| Genzyme Corporation | $17.95 | 2025 | |
| Lilly USA, LLC | $17.64 | 2025 | Zepbound |
| Sanofi-Aventis U.S. LLC | $17.02 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $16.67 | 2023 | Uptravi, Opsumit |
| Esperion Therapeutics, INC. | $16.02 | 2024 | Nexletol |
| Kiniksa Pharmaceuticals International, Plc | $14.38 | 2024 | Arcalyst |
| Daiichi Sankyo INC. | $13.65 | 2024 | Injectafer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Kern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.